By Chris Wack


Hoth Therapeutics shares were up 14% to $1.47 after the company received U.S. Food and Drug Administration clearance to implement a number of protocol amendments to its ongoing clinical trial for HT-001.

The stock hit its 52-week low of 99 cents on Nov. 15, and is down 74% in the past 12 months.

The biopharmaceutical company's HT-001 is being developed as a potential treatment for cancer patients undergoing treatment of skin toxicities associated with Epidermal Growth Factor Receptor Inhibitors.

The trial is being conducted under Hoth's open Investigational New Drug Application for HT-001.

The goal of the study is to determine the minimum efficacious dose strength for further investigation. The dose effect, together with the application site safety assessments, and therapeutic effects based on the primary and secondary endpoints will be evaluated.


Write to Chris Wack at chris.wack@wsj.com


(END) Dow Jones Newswires

01-18-24 1111ET